Recruiting

Testing a preventive drug to reduce severe side effects during myeloma treatment

Plain-English translation of NCT07589634 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Multiple Myeloma research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a single dose of —a medication that calms the immune system—given before treatment can prevent or reduce a serious side effect called cytokine release syndrome (CRS). CRS is an inflammatory reaction that can cause flu-like symptoms, fever, and fatigue. Half of participants will receive before the medication, and half will receive a placebo (salt water) to see which group experiences fewer or less severe symptoms.

is a promising new treatment for myeloma that has come back or stopped working, but it can trigger a harmful inflammatory reaction in the body. This trial is testing whether protecting patients in advance with a preventive drug can make the treatment safer and more tolerable.

Do you qualify?

You likely qualify if…

you have been diagnosed with multiple myeloma that has come back (relapsed) or stopped responding (become refractory) to at least one prior treatment
you have measurable disease that can be tracked during the study
you are in reasonably good health overall (an ECOG performance status of 0 to 2, which means you can care for yourself and carry out light activities)
you have normal or near-normal blood work results at the start of the study

You likely don't qualify if…

you are currently taking other cancer treatments or investigational drugs at the same time
you have had major surgery within the past 2 weeks or are planning surgery during the study
you are allergic or have had severe reactions to ramantamig, tocilizumab, or similar drugs
you have myeloma that has spread to your brain or spinal fluid, or you show signs of meningeal involvement
you have another active cancer (other than myeloma) that is considered high-risk and requires treatment

What participation looks like

You will be randomly assigned to one of two groups: one receiving before starting , and one receiving placebo before starting . Both groups will receive and continue treatment until your disease improves, worsens, or side effects become too severe. The study will closely monitor you for inflammatory symptoms over the first 28 days and continue tracking your health throughout the treatment period.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Testing a preventive drug to reduce severe side effects during myeloma treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(4 sites)